Trial reportClinical pharmacology and therapeutics2009
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Trial report in Clinical pharmacology and therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 6 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022Pooled it
- Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.Pharmacogenomics · 2018Pooled it
- From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Pharmacogenomics · 2018Pooled it
- Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.The Cochrane database of systematic reviews · 2017Pooled it
- Individual behavioural counselling for smoking cessation.The Cochrane database of systematic reviews · 2017Pooled it
- Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence.Psychopharmacology · 2011Pooled it
- The Nicotine Metabolite Ratio and Response to Smoking Cessation Treatment Among People Living with HIV Who Smoke in South Africa.International journal of environmental research and public health · 2025Trial
- Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.Experimental and clinical psychopharmacology · 2022Trial
- Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation: Secondary Analysis of the EAGLES Randomized Clinical Trial.JAMA network open · 2021Trial
- Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.British journal of clinical pharmacology · 2019Trial
- Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Trial
- Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking.Pharmacology, biochemistry, and behavior · 2016Trial
- The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Trial
- Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.The Lancet. Respiratory medicine · 2015Trial
- Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers.Clinical pharmacology and therapeutics · 2014Trial
- Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.Addictive behaviors · 2013Trial
- Dose-independent kinetics with low level exposure to nicotine and cotinine.British journal of clinical pharmacology · 2013Trial
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Cytochrome P450 2A6 (CYP2A6) is the main nicotine (NIC)-metabolizing enzyme in humans. We investigated the relationships between CYP2A6 genotype, baseline plasma trans- 3'-hydroxycotinine/cotinine (3HC/COT) (a phenotypic marker of CYP2A6 activity), and smoking behavior in African-American light smokers. Cigarette consumption, age of initiation, and dependence scores did not differ among 3HC/COT quartiles or CYP2A6 genotype groups. Slow metabolizers (SMs; both genetic and phenotypic) had significantly higher plasma NIC levels, suggesting that cigarette consumption was not reduced to adjust for slower rates of NIC metabolism. Individuals in the slowest 3HC/COT quartile had higher quitting rates with both placebo and NIC gum treatments (odds ratio 1.85, 95% confidence interval (CI) 1.08-3.16, P = 0.03). Similarly, the slowest CYP2A6 genotype group had higher quitting rates, although this trend did not reach significance (odds ratio 1.61, 95% CI 0.95-2.72, P = 0.08). The determination of the 3HC/COT ratio, and possibly CYP2A6 genotype, may be useful in the future for personalizing the choice of smoking cessation treatment in African-American light smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.